News for Alnylam Pharmaceuticals, Inc. (ALNY)

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Summary: Alnylam Pharmaceuticals' Amvuttra gains European Commission approval for hereditary transthyretin amyloidosis and cardiomyopathy. Analysts forecast

Summary Alnylam Pharmaceuticals Inc (ALNY), a leader in RNA interference (RNAi) therapeutics, announced that the European Commission has approved AMVUTTRA® (vu

However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and...

Alnylam Pharmaceuticals (ALNY) showcased the latest insights from its HELIOS-B Phase 3 study at the Heart Failure 2025 Congress in Belgrade, Serbia. The study e

Alnylam Pharmaceuticals' Phase 3 HELIOS-B trial reveals significant results for Amvuttra in reducing mortality for ATTR amyloidosis patients. Analyst pr

Summary Alnylam Pharmaceuticals Inc (ALNY), a leader in RNAi therapeutics, presented new findings from the HELIOS-B Phase 3 study at the Heart Failure 2025 Cong

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data

Alnylam Pharmaceuticals (ALNY) is set to reveal new findings from its transthyretin amyloidosis portfolio at the Heart Failure 2025 Congress, hosted by the Euro

Alnylam Pharmaceuticals (ALNY) to present new HELIOS-B Phase 3 study data at Heart Failure 2025 Congress. HELIOS-B study supports vutrisiran (AMVUTTRA®

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tob

**media[618065]**

**media[617621]**

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overvi

Alnylam Pharmaceuticals, Inc. (ALNY) to present at the BofA Securities 2025 Health Care Conference on May 14, 2025. The webcast of the presentation will

On May 2, 2025, UBS analyst Esther Rajavelu announced a positive update regarding Alnylam Pharmaceuticals (ALNY). UBS has maintained its \

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...